In $69M IPO bid, GlobeImmune spotlights therapeutic vaccines

GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.

The biotech (a 2008 Fierce 15 company) has built a pipeline of immunotherapies around its Tarmogens platform, a method of activating the immune system by stimulating cellular immunity. Two of its most advanced programs include GI-4000, a cancer product candidate in a Phase IIb trial for pancreatic cancer and GI-5005, which has been tested to combat the hepatitis C virus. The company comes to the table with a strategic collaboration with Celgene ($CELG) focused in oncology and a separate pact with Gilead Sciences ($GILD) for its candidates against chronic hepatitis B infections.

GlobeImmune wants to use proceeds from the IPO to ready its manufacturing facility and process for commercial-scale production, support clinical trials, gain working capital and provide funding for other general corporate purposes, according to The Wall Street Journal.

Public investors have made similar gambles recently. For instance, NewLink Genetics, another therapeutic vaccine developer, raised $43.4 million in a November IPO after cutting its stock price.

- read the S-1
- see the Wall Street Journal article
- and Reuters' report

Special Report: GI-4000 - 10 Promising Therapeutic Vaccines

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.